Inotiv, Inc. Files Definitive Proxy Statement for 2024 Annual Meeting

Ticker: NOTV · Form: DEF 14A · Filed: Jan 26, 2024 · CIK: 720154

Complexity: simple

Sentiment: neutral

Topics: Proxy Statement, Inotiv, NOTV, Non-human primates, Discovery and Safety Assessment

TL;DR

<b>Inotiv, Inc. reports on fiscal 2023 strategies, including facility consolidation and enhanced animal sourcing, alongside strong growth in its Discovery and Safety Assessment segment.</b>

AI Summary

Inotiv, Inc. (NOTV) filed a Proxy Statement (DEF 14A) with the SEC on January 26, 2024. Inotiv maintained similar revenue in its RMS operations despite reduced non-human primate availability. The company reduced its operating facilities from 35 to 24 between September 30, 2022, and September 30, 2023. Inotiv identified and audited multiple additional sources for purpose-bred animals. Novel genetic testing techniques were developed and sourced to bolster auditing capabilities for purpose-bred animals. Discovery and Safety Assessment operations achieved 12% year-over-year revenue growth in fiscal 2023.

Why It Matters

For investors and stakeholders tracking Inotiv, Inc., this filing contains several important signals. The company's focus on rightsizing its operating footprint by reducing facilities aims to improve capital deployment efficiency. Development of novel genetic testing techniques and diversification of animal sources are strategic responses to supply chain challenges in the non-human primate market.

Risk Assessment

Risk Level: medium — Inotiv, Inc. shows moderate risk based on this filing. The company faces ongoing challenges with the reduced availability of non-human primates, which impacts its RMS operations and requires strategic sourcing and auditing efforts.

Analyst Insight

Shareholders should monitor Inotiv's progress in diversifying animal sources and implementing new genetic testing techniques to mitigate supply chain risks.

Financial Highlights

debt To Equity
N/A
revenue
N/A
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
N/A
eps
N/A
gross Margin
N/A
cash Position
N/A
revenue Growth
N/A

Revenue Breakdown

SegmentRevenueGrowth
Discovery and Safety AssessmentN/A12%

Key Numbers

Key Players & Entities

Forward-Looking Statements

FAQ

When did Inotiv, Inc. file this DEF 14A?

Inotiv, Inc. filed this Proxy Statement (DEF 14A) with the SEC on January 26, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Inotiv, Inc. (NOTV).

Where can I read the original DEF 14A filing from Inotiv, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Inotiv, Inc..

What are the key takeaways from Inotiv, Inc.'s DEF 14A?

Inotiv, Inc. filed this DEF 14A on January 26, 2024. Key takeaways: Inotiv maintained similar revenue in its RMS operations despite reduced non-human primate availability.. The company reduced its operating facilities from 35 to 24 between September 30, 2022, and September 30, 2023.. Inotiv identified and audited multiple additional sources for purpose-bred animals..

Is Inotiv, Inc. a risky investment based on this filing?

Based on this DEF 14A, Inotiv, Inc. presents a moderate-risk profile. The company faces ongoing challenges with the reduced availability of non-human primates, which impacts its RMS operations and requires strategic sourcing and auditing efforts.

What should investors do after reading Inotiv, Inc.'s DEF 14A?

Shareholders should monitor Inotiv's progress in diversifying animal sources and implementing new genetic testing techniques to mitigate supply chain risks. The overall sentiment from this filing is neutral.

Risk Factors

Key Dates

Filing Stats: 4,620 words · 18 min read · ~15 pages · Grade level 15.2 · Accepted 2024-01-25 21:24:15

Filing Documents

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 29 DELINQUENT SECTION 16 (a) REPORTS 30 SHAREHOLDER PROPOSALS FOR 2025 ANNUAL MEETING 30 OTHER BUSINESS 30 APPENDIX A – INOTIV, INC. 2024 EQUITY INCENTIVE PLAN 31 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This proxy statement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected, expressed, or implied by such forward-looking information. Risks and uncertainties that could cause or contribute to such differences include, but are not limited to, those discussed in Part I, Item 1A, "Risk Factors" included in our Annual Report on Form 10-K for the fiscal year ended September 30, 2023, as may be updated in our subsequent Quarterly Reports on Form 10-Q. Readers of this proxy statement are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. We expressly disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. INOTIV, INC. PROXY STATEMENT ANNUAL MEETING OF SHAREHOLDERS MARCH 14, 2024 GENERAL This proxy statement is furnished by Inotiv, Inc. ("Inotiv," the "Company," "we," "us," or "our") in connection with the solicitation by the Board of Directors of the Company of proxies to be voted at the Annual Meeting of Shareholders (the "Annual Meeting") to be held at 1000 a.m. (ET) on Thursday, March 14, 2024, and at any adjournment thereof. The meeting will be held at the Courtyard Marriott Lafayette, 150 Fairington Avenue, Lafayette, Indiana 47905. A shareholder who properly submits a proxy may revoke it at any time before it is exercised by delivering written notice to the Secretary of the Company, by timely submitt

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing